A lab compound used to block scarring has a hidden second job: hijacking the cell's recycling system

A lab compound long studied for blocking scar formation has a separate function that researchers can now use as a tool in fibrosis, cardiac remodelling, hypertrophic cardiomyopathy, and cancer biology. SD-208, an inhibitor of the TGF-β receptor ALK5, suppresses the release of small extracellular vesicles from cardiac fibroblasts and HEK293 cells by rerouting them into the cell's lysosome, according to a peer-reviewed paper in the Journal of Extracellular Vesicles published this month.

SD-208's canonical action blocks the TGF-β/Smad cascade; the vesicle-suppression effect persists in non-activated cardiac fibroblasts and non-fibrotic HEK293 cells where the Smad pathway is silent. Proteomic profiling of treated cells points to disrupted vesicle trafficking and accelerated transport of endosomes to the lysosome.

The cargo, CD63-positive vesicles, normally ferries molecular messages between cells. After SD-208 treatment, these compartments accumulate inside the cell and are selectively diverted into LAMP1-positive lysosomes for degradation.

The authors frame the finding as a research tool, not a treatment. SD-208 lets labs controllably probe the fate decision between secretion and degradation of multivesicular bodies. Earlier conference reports from the same group and at the UKEV Forum 2024 tracked the trajectory before formal publication.

Clinical translation is not on the table. The work is in cell lines, not patients.